Design and synthesis of rosiglitazone-ferulic acid-nitric oxide donor trihybrids for improving glucose tolerance

Jingchao Liu, Zhangjian Huang, Wenhuan Ma, Sixun Peng, Yunman Li, Katrina M Miranda, Jide Tian, Yihua Zhang

Research output: Contribution to journalArticle

Abstract

Glucose intolerance is associated with metabolic syndrome and type 2 diabetes mellitus (T2DM) while some new therapeutic drugs, such as rosiglitazone (Rosi), for T2DM can cause severe cardiovascular side effects. Herein we report the synthesis of Rosi-ferulic acid (FA)-nitric oxide (NO) donor trihybrids to improve glucose tolerance and minimize the side effects. In comparison with Rosi, the most active compound 21 exhibited better effects on improving glucose tolerance, which was associated with its NO production, antioxidant and anti-inflammatory activities. Furthermore, 21 displayed relatively high stability in the simulated gastrointestinal environments and human liver microsomes, and released Rosi in plasma. More importantly, 21, unlike Rosi, had little stimulatory effect on the membrane translocation of aquaporin-2 (AQP2) in kidney collecting duct epithelial cells. These, together with a better safety profile, suggest that the trihybrids, like 21, may be promising candidates for intervention of glucose intolerance-related metabolic syndrome and T2DM.

LanguageEnglish (US)
Pages650-665
Number of pages16
JournalEuropean journal of medicinal chemistry
Volume162
DOIs
StatePublished - Jan 15 2019

Fingerprint

ferulic acid
rosiglitazone
Nitric Oxide Donors
Glucose
Medical problems
Type 2 Diabetes Mellitus
Glucose Intolerance
Collecting Kidney Tubules
Aquaporin 2
Liver Microsomes
Liver
Ducts
Nitric Oxide
Anti-Inflammatory Agents
Antioxidants
Epithelial Cells
Membranes
Plasmas
Safety

Keywords

  • Ferulic acid
  • Glucose intolerance
  • Nitric oxide
  • Rosiglitazone
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Design and synthesis of rosiglitazone-ferulic acid-nitric oxide donor trihybrids for improving glucose tolerance. / Liu, Jingchao; Huang, Zhangjian; Ma, Wenhuan; Peng, Sixun; Li, Yunman; Miranda, Katrina M; Tian, Jide; Zhang, Yihua.

In: European journal of medicinal chemistry, Vol. 162, 15.01.2019, p. 650-665.

Research output: Contribution to journalArticle

Liu, Jingchao ; Huang, Zhangjian ; Ma, Wenhuan ; Peng, Sixun ; Li, Yunman ; Miranda, Katrina M ; Tian, Jide ; Zhang, Yihua. / Design and synthesis of rosiglitazone-ferulic acid-nitric oxide donor trihybrids for improving glucose tolerance. In: European journal of medicinal chemistry. 2019 ; Vol. 162. pp. 650-665.
@article{a0d0c6f233074d4786821011c85a053e,
title = "Design and synthesis of rosiglitazone-ferulic acid-nitric oxide donor trihybrids for improving glucose tolerance",
abstract = "Glucose intolerance is associated with metabolic syndrome and type 2 diabetes mellitus (T2DM) while some new therapeutic drugs, such as rosiglitazone (Rosi), for T2DM can cause severe cardiovascular side effects. Herein we report the synthesis of Rosi-ferulic acid (FA)-nitric oxide (NO) donor trihybrids to improve glucose tolerance and minimize the side effects. In comparison with Rosi, the most active compound 21 exhibited better effects on improving glucose tolerance, which was associated with its NO production, antioxidant and anti-inflammatory activities. Furthermore, 21 displayed relatively high stability in the simulated gastrointestinal environments and human liver microsomes, and released Rosi in plasma. More importantly, 21, unlike Rosi, had little stimulatory effect on the membrane translocation of aquaporin-2 (AQP2) in kidney collecting duct epithelial cells. These, together with a better safety profile, suggest that the trihybrids, like 21, may be promising candidates for intervention of glucose intolerance-related metabolic syndrome and T2DM.",
keywords = "Ferulic acid, Glucose intolerance, Nitric oxide, Rosiglitazone, Type 2 diabetes mellitus",
author = "Jingchao Liu and Zhangjian Huang and Wenhuan Ma and Sixun Peng and Yunman Li and Miranda, {Katrina M} and Jide Tian and Yihua Zhang",
year = "2019",
month = "1",
day = "15",
doi = "10.1016/j.ejmech.2018.10.006",
language = "English (US)",
volume = "162",
pages = "650--665",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Design and synthesis of rosiglitazone-ferulic acid-nitric oxide donor trihybrids for improving glucose tolerance

AU - Liu, Jingchao

AU - Huang, Zhangjian

AU - Ma, Wenhuan

AU - Peng, Sixun

AU - Li, Yunman

AU - Miranda, Katrina M

AU - Tian, Jide

AU - Zhang, Yihua

PY - 2019/1/15

Y1 - 2019/1/15

N2 - Glucose intolerance is associated with metabolic syndrome and type 2 diabetes mellitus (T2DM) while some new therapeutic drugs, such as rosiglitazone (Rosi), for T2DM can cause severe cardiovascular side effects. Herein we report the synthesis of Rosi-ferulic acid (FA)-nitric oxide (NO) donor trihybrids to improve glucose tolerance and minimize the side effects. In comparison with Rosi, the most active compound 21 exhibited better effects on improving glucose tolerance, which was associated with its NO production, antioxidant and anti-inflammatory activities. Furthermore, 21 displayed relatively high stability in the simulated gastrointestinal environments and human liver microsomes, and released Rosi in plasma. More importantly, 21, unlike Rosi, had little stimulatory effect on the membrane translocation of aquaporin-2 (AQP2) in kidney collecting duct epithelial cells. These, together with a better safety profile, suggest that the trihybrids, like 21, may be promising candidates for intervention of glucose intolerance-related metabolic syndrome and T2DM.

AB - Glucose intolerance is associated with metabolic syndrome and type 2 diabetes mellitus (T2DM) while some new therapeutic drugs, such as rosiglitazone (Rosi), for T2DM can cause severe cardiovascular side effects. Herein we report the synthesis of Rosi-ferulic acid (FA)-nitric oxide (NO) donor trihybrids to improve glucose tolerance and minimize the side effects. In comparison with Rosi, the most active compound 21 exhibited better effects on improving glucose tolerance, which was associated with its NO production, antioxidant and anti-inflammatory activities. Furthermore, 21 displayed relatively high stability in the simulated gastrointestinal environments and human liver microsomes, and released Rosi in plasma. More importantly, 21, unlike Rosi, had little stimulatory effect on the membrane translocation of aquaporin-2 (AQP2) in kidney collecting duct epithelial cells. These, together with a better safety profile, suggest that the trihybrids, like 21, may be promising candidates for intervention of glucose intolerance-related metabolic syndrome and T2DM.

KW - Ferulic acid

KW - Glucose intolerance

KW - Nitric oxide

KW - Rosiglitazone

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85056997614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056997614&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2018.10.006

DO - 10.1016/j.ejmech.2018.10.006

M3 - Article

VL - 162

SP - 650

EP - 665

JO - European Journal of Medicinal Chemistry

T2 - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -